BTIG Keeps a Hold Rating on Regeneron

By Ryan Adsit

In a report released yesterday, Dane Leone from BTIG maintained a Hold rating on Regeneron (NASDAQ: REGN). The company’s shares closed yesterday at $344.55, close to its 52-week low of $313.53.

According to, Leone is a 5-star analyst with an average return of 21.7% and a 72.7% success rate. Leone covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Voyager Therapeutics Inc, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $431.81, representing a 25.3% upside.

In a report released yesterday, Oppenheimer also reiterated a Hold rating on the stock.

Regeneron’s market cap is currently $37.08B and has a P/E ratio of 33.39. The company has a book value ratio of 6.0354.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in inventing medicines for people with serious diseases. It includes Arcalyst, Dupixent, Eylea, Kevzara, and Praluent injections. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.